Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review
| Autor: | Marcus Rafael Lobo Bezerra, Larissa Queiroz Pontes, Carla F. C. Fernandes, Marcela Helena Gambim Fonseca, Gilvan Pessoa Furtado |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.drug_class medicine.medical_treatment Antibody Affinity Carbohydrates Receptors Fc Protein Engineering Monoclonal antibody Biochemistry Structure-Activity Relationship 03 medical and health sciences Neonatal Fc receptor Structural Biology medicine Animals Humans Molecular Biology biology business.industry Effector Antibodies Monoclonal General Medicine Immunotherapy Fragment crystallizable region Immunoglobulin Fc Fragments 030104 developmental biology Biopharmaceutical Immunoglobulin G Immunology biology.protein Fc-Gamma Receptor Antibody business Protein Binding |
| Zdroj: | International Journal of Biological Macromolecules. 119:306-311 |
| ISSN: | 0141-8130 |
| Popis: | Due mainly to their high level of affinity and specificity, therapeutic monoclonal antibodies (mAbs) have been frequently selected as treatment for cancer, autoimmune or chronic inflammatory diseases. Despite the increasing number of mAbs and related products in the biopharmaceutical market, they are still expensive, can cause undesired side effects, and eventually cause resistance. Antibody engineering, which emerged to overcome limitations faced by mAb therapy, has supported the development of modified mAbs for immunotherapy. As part of this approach, researchers have invested in obtaining antibody fragments, as well as in Fc region modifications, since interactions with Fc receptors influence an antibody's half-life and mechanism of action. Thus, Fc engineering results in antibodies with more desirable characteristics and functions for which they are intended, creating "fit-for-purpose" antibodies with reduced side effects. Furthermore, aglycosylated antibodies, produced in bacterial cultivation, have been an alternative to create new effector functional human immunotherapeutics, while reducing mAb therapy costs. This review highlights some features that enhance mAb performance, related to the improvement of antibody half-life and effector responses by both Fc-engineering and glycoengineering. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect